scholarly journals Prescription Opioids Dispensed to Patients with Cancer with Bone Metastasis: 2011‐2017

2021 ◽  
Author(s):  
Hao Zhang ◽  
Judith Paice ◽  
Russell Portenoy ◽  
Eduardo Bruera ◽  
M Carrington Reid ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Prescription Opioids ◽  
Patients With Cancer

scholarly journals Physiopathology of Spine Metastasis

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Giulio Maccauro ◽  
Maria Silvia Spinelli ◽  
Sigismondo Mauro ◽  
Carlo Perisano ◽  
Calogero Graci ◽  
...  
Keyword(s):  
Growth Factors ◽  
Bone Metastasis ◽  
Lymphatic System ◽  
Spinal Metastasis ◽  
Bone Destruction ◽  
The Body ◽  
Vicious Cycle ◽  
Patients With Cancer ◽  
Local Tumour ◽  
Neurological Injuries

The metastasis is the spread of cancer from one part of the body to another. Two-thirds of patients with cancer will develop bone metastasis. Breast, prostate and lung cancer are responsible for more than 80% of cases of metastatic bone disease. The spine is the most common site of bone metastasis. A spinal metastasis may cause pain, instability and neurological injuries. The diffusion through Batson venous system is the principal process of spinal metastasis, but the dissemination is possible also through arterial and lymphatic system or by contiguity. Once cancer cells have invaded the bone, they produce growth factors that stimulate osteoblastic or osteolytic activity resulting in bone remodeling with release of other growth factors that lead to a vicious cycle of bone destruction and growth of local tumour.

scholarly journals Risk Evaluation of Denosumab And Zoledronic Acid For Medication-Related Osteonecrosis of The Jaw In Patients With Bone Metastases: A Propensity Score-Matched Analysis

2021 ◽  
Author(s):  
Hiroaki Ikesue ◽  
Kohei Doi ◽  
Mayu Morimoto ◽  
Masaki Hirabatake ◽  
Nobuyuki Muroi ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Metastasis ◽  
Propensity Score ◽  
Proportional Hazards ◽  
Significant Risk ◽  
Patient Characteristics ◽  
Osteonecrosis Of The Jaw ◽  
Cox Proportional Hazards ◽  
Close Monitoring ◽  
Patients With Cancer

Abstract Purpose: This study evaluated the risk of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer who received denosumab or zoledronic acid (ZA) for treating bone metastasis.Methods: The medical records of patients were retrospectively reviewed. Patients who did not undergo a dental examination at baseline were excluded. The primary endpoint was a comparison of the risk of developing MRONJ between the denosumab and ZA groups. Propensity score matching was used to control for baseline differences between patient characteristics and compare outcomes for both groups.Results: Among the 799 patients enrolled, 58 (7.3%) developed MRONJ. The incidence of MRONJ was significantly higher in the denosumab group than in the ZA group (9.6% [39/406] vs. 4.8% [19/393], p = 0.009). Multivariate Cox proportional hazards regression analysis revealed that denosumab treatment (hazard ratio [HR], 2.89; 95% confidence interval [CI], 1.65–5.25; p < 0.001) and tooth extraction after starting ZA or denosumab (HR, 4.26; 95% CI, 2.38–7.44; p < 0.001) were significant risk factors for MRONJ. Propensity score-matched analysis confirmed that the risk of developing MRONJ was significantly higher in the denosumab group than in the ZA group (HR, 2.34; 95% CI, 1.17–5.01; p = 0.016). Conclusion: The results of this study suggest that denosumab poses a significant risk for developing MRONJ in patients treated for bone metastasis, and thus these patients require close monitoring.

Descriptive analysis of bisphosphonates use in patients with cancer and bone metastasis

Bone ◽  
2006 ◽  
Vol 38 (3) ◽  
pp. 78
Author(s):  
V. Launay-Vacher ◽  
S. Oudard ◽  
N. Janus ◽  
C. Le Tourneau ◽  
O. Rixe ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Descriptive Analysis ◽  
Patients With Cancer

scholarly journals Preventing Discontinuation of Radiation Therapy: Predictive Factors to Improve Patient Selection for Palliative Treatment

2017 ◽  
Vol 13 (9) ◽  
pp. e782-e791 ◽  
Author(s):  
Lindsay L. Puckett ◽  
Eric Luitweiler ◽  
Louis Potters ◽  
Sewit Teckie
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Bone Metastasis ◽  
Brain Metastases ◽  
Patient Selection ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Factors Associated ◽  
Patients With Cancer ◽  
Selection For

Purpose: Approximately one third of patients with cancer require palliative radiation therapy (PRT), yet no guidelines exist for optimal patient selection. We have observed that many patients who begin PRT do not complete their prescribed treatment. Our study sought to identify factors associated with discontinuation of PRT, assess for a relationship with survival, and inform patient selection. Methods: We performed an institutional review board–approved retrospective analysis of patients with cancer treated in a multicenter radiation oncology department in 2014. Of 297 patients who began PRT, 60 discontinued and 237 completed treatment. Primary end points included discontinuation and overall survival. Results: Patient factors were analyzed for association with discontinuation of PRT and overall survival, respectively, using logistic regression and Cox proportional regression models. Factors associated with discontinuation were low Karnofsky performance status (KPS) score, high number of fractions prescribed, and treatment site other than bone metastasis. The odds of discontinuing PRT decreased by approximately 52% for every 10-point increase in KPS score (odds ratio, 0.48; 95% CI, 0.36 to 0.63; P < .001). Factors associated with shorter survival included discontinuation of PRT, low KPS score, community practice location, multiple comorbidities, and treatment of brain metastases. Patients who discontinued treatment were more likely to die than patients who completed treatment, independent of other factors (hazard ratio, 3.67; 95% CI, 2.41 to 5.61; P < .001). Conclusion: Patients with low KPS scores, long treatment courses, and those treated to sites other than bone metastasis were significantly more likely to discontinue treatment. Discontinuation was predictive for poor survival. Pretreatment evaluation of KPS, comorbidities, and brain metastases can help guide appropriate patient selection for PRT.

scholarly journals Multimodal Imaging-Based Potential Visualization of the Tumor Microenvironment in Bone Metastasis

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 2877
Author(s):  
Jang Bae Moon ◽  
Su Woong Yoo ◽  
Changho Lee ◽  
Dong-Yeon Kim ◽  
Ayoung Pyo ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Tumor Microenvironment ◽  
Multimodal Imaging ◽  
Imaging Techniques ◽  
Management Plan ◽  
Imaging Modalities ◽  
Multiple Site ◽  
Factors Affecting ◽  
Patients With Cancer ◽  
Site Evaluation

Bone metastasis (BM) is the most common malignant bone tumor and a significant cause of morbidity and mortality for patients with cancer. Compared to other metastatic organs, bone has unique characteristics in terms of the tumor microenvironment (TME). Precise assessments of the TME in BM could be an important step for developing an optimized management plan for patient care. Imaging approaches for BM have several advantages, such as biopsy not being required, multiple site evaluation, and serial assessment in the same sites. Owing to the developments of new imaging tracers or imaging modalities, bone TME could be visualized using multimodal imaging techniques. In this review, we describe the BM pathophysiology, diagnostic principles of major imaging modalities, and clinically available imaging modalities to visualize the TME in BM. We also discuss how the interactions between various factors affecting the TME could be visualized using multimodal imaging techniques.

Wernicke encephalopathy without delirium in patients with cancer

2017 ◽  
Vol 16 (1) ◽  
pp. 118-121 ◽  
Author(s):  
Hideki Onishi ◽  
Mayumi Ishida ◽  
Iori Tanahashi ◽  
Takao Takahashi ◽  
Yoshitada Taji ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Gait Disturbance ◽  
Wernicke Encephalopathy ◽  
Appetite Loss ◽  
Laboratory Findings ◽  
Patients With Cancer ◽  
Non Hodgkin Lymphoma ◽  
Outpatient Visits ◽  
Unsteady Gait ◽  
Loss Of Appetite

ABSTRACTObjective:Wernicke encephalopathy (WE) is a neuropsychiatric disorder caused by thiamine deficiency. Several reports of WE in cancer patients are known. WE is sometimes overlooked because most patients do not exhibit its typical symptoms (e.g., delirium, ataxia, ocular palsy). If delirium is not present, a diagnosis of WE is difficult because delirium is the hallmark symptom of WE.Method:Taken from a series on WE in cancer, we report two patients who developed WE without delirium during periodic psycho-oncology outpatient visits.Results:Case 1. A 61-year-old woman with non-Hodgkin lymphoma who was periodically attending a psycho-oncology outpatient clinic developed an unsteady gait. WE was suspected because she also developed appetite loss for two weeks, and we could find no other laboratory findings to explain her unsteady gait. Our diagnosis was supported by abnormal serum thiamine and disappearance of the gait disturbance after intravenous thiamine administration. Case 2. A 50-year-old woman with breast carcinoma with bone metastasis developed an unsteady gait. WE was suspected because she also developed loss of appetite for two weeks, and no other laboratory findings could explain her unsteady gait. The diagnosis was supported by abnormal serum thiamine and disappearance of the gait disturbance after administration of intravenous thiamine.Significance of Results:Our report emphasizes the importance of being aware of WE, even when patients do not present with delirium. The presence of loss of appetite for more than two weeks may be the key to a diagnosis of WE.

466: Age is an Independent Predictor of Bone Metastasis at Prostate Cancer Diagnosis

2007 ◽  
Vol 177 (4S) ◽  
pp. 156-156
Author(s):  
Andrea Salonia ◽  
Pierre I. Karakiewicz ◽  
Andrea Gallina ◽  
Alberto Briganti ◽  
Tommaso C. Camerata ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Cancer Diagnosis ◽  
Independent Predictor ◽  
Prostate Cancer Diagnosis

664: CXCL12/CXCR4 Trans-Activation of HER2 in Lipid Rafts of Prostate Cancer Cell Membranes Promotes Bone Metastasis

2007 ◽  
Vol 177 (4S) ◽  
pp. 223-223
Author(s):  
Sreenivasa R. Chinni ◽  
Hamilto Yamamoto ◽  
Zhong Dong ◽  
Aaron Sabbota ◽  
Sanaa Nabha ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Lipid Rafts ◽  
Cancer Cell ◽  
Cell Membranes ◽  
Prostate Cancer Cell
Sign in / Sign up

Export Citation Format

Share Document